What do you do with MTX in RA-ILD patients?
1. RA dx activity drives RA-ILD
2. MTX is a cornerstone of effective RA therapy
3. MTX not a/w increased RA-ILD
4. MTX pneunonitis is very rare
You do the math. Critical for our patients
#ARANZRA24
What leads to flares of gout?
(That’s different to what causes gout in the first place. What triggers it off?)
risks:
- all types of alcohol
- hotter climates, extremes of humidity
- animal > veg purines
protective:
- omega 3
- cherries - but to a limit!
@Tuhina_Neogi#ARANZRA24
Morning CTD- ILD session in an MDT format by Prof Mandana Nikpour, Dr Matt Parker and Dr John Mackintosh. Case based discussions and real world management challenges #ARANZRA24#ARANZRA
A year in review! Informative talks by Prof Rebecca Grainger, Prof Eric Morand and Prof Marinka Twilt #ARANZRA . Interspersed with laugh, excellent take home messages!
Excellent talks by Stephen Bird, Julia Martin and our very own WA based Julia Murdoch at the US workshop. Learnt a lot including a practical session on vascular imaging 🧐#ARANZRA24
As an editor, I often read discussions that are long winded, meandering and fail to make an impact.
They feel like an after-thought rather than a key part of the paper.
Here are some tips to make your discussion better. Full credit to @sanjaysaint who taught me this years ago!
The Phase 3 trial of Sirolimus (Rapamycin) for the treatment of inclusion body myositis (IBM) has begun! Congratulations, and thanks, to everyone who helped make this happen.